EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA12 addresses ‘Glasdegib indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML)’, submitted by Pfizer. We are delighted that HVB and
The minutes from the EMA-EUnetHTA Meeting, hosted by the European Medicines Agency on 7th December 2018, are now available for access. This was the 16th meeting between the EMA and EUnetHTA, with representatives from both organisations in attendance as well as
The minutes from the EUnetHTA-EFPIA Technical Meeting, held on 11th December 2018 at the Haute Autorité de Santé in Paris, are now available for access. Participants included attendees from both EFPIA and EUnetHTA, as well as the EMA and DG SANTE.
PTJA11 addresses 'cefiderocol the for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’, submitted by Shionogi BV. We are delighted that AIFA and NOMA are authoring this assessment. We will be issuing an
Open Call for Patient Group Input – Collaborative Assessment on a Medical Device for Rectum Spaces for Prostate Cancer Radiotherapy
EUnetHTA recently started a new Collaborative Assessment on a Medical Device for rectum spacers for prostate cancer radiotherapy. To find out about participation, please read more here. Input submissions will be received through EOB, Friday 5th July.
We are pleased to announce that the collaborative rapid assessment, OTCA11, on "Custom-made or customisable 3D printed implants and cutting guides versus non-3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery"
Minutes of 5 July 2018 EMA/EUnetHTA meeting [pdf-embedder url="https://eunethta.eu/wp-content/uploads/2018/11/Minutes-of-the-EMAEUnetHTA-meeting-5-July-2018.pdf" title="Minutes of the EMAEUnetHTA meeting - 5 July 2018"]